However, anti-PD-1/PD-L1 based monotherapy could not prolong PFS than chemotherapy in NSCLC patients with LM while anti-PD-1/PD-L1 based combination therapy could dramatically prolong both PFS and OS. The gene discussed is CD274; the disease is non-small cell lung carcinoma.